Hikal Ltd Q1FY27 Revenue ₹403 Cr, EBITDA Margin Expands 260 bps
Hikal Ltd. reported its unaudited financial results for the quarter ended June 30, 2026. Revenue stood at ₹403 Crores, a 6.2% increase year-on-year, despite geopolitical and macroeconomic headwinds. EBITDA margin expanded by 260 basis points year-on-year to 9.2%, with quarterly EBITDA growing 47.4% YoY to ₹37 Crores. The Pharmaceutical business showed recovery, contributing 58% of revenue with ₹233 Crores, driven by improving customer offtake and regulated market demand. The Crop Protection business faced margin pressure due to higher input costs and customer inventory adjustments, though Own Products saw volume-led growth. The company expects business momentum to strengthen progressively through FY27.
Key Highlights
- Revenue grew 6.2% YoY to ₹403 Cr, driven by execution.
- EBITDA margin expanded 260 bps YoY to 9.2%.
- Pharmaceuticals revenue up 15.2% YoY to ₹233 Cr.
- Crop Protection faced input cost pressures and inventory adjustments.
- Business momentum expected to strengthen in FY27.
Price Impact
More from HIKAL